Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Precipio, Inc. stock logo
PRPO
Precipio
$6.65
+0.2%
$6.22
$3.90
$10.74
$10.08M1.129,058 shs2,862 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.17
+0.6%
$2.88
$1.75
$9.37
$5.09M1.66845,791 shs90,989 shs
SeqLL Inc. stock logo
SQL
SeqLL
$4.16
$6.50
$96.00
$2.12M1.3452,119 shs1,731 shs
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$1.41
-11.9%
$1.62
$1.04
$9.53
$2.57M1.333,032 shs372 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Precipio, Inc. stock logo
PRPO
Precipio
+0.24%+5.32%+17.42%-10.43%+10.12%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+0.63%-7.58%+38.43%+22.87%+2,078.69%
SeqLL Inc. stock logo
SQL
SeqLL
0.00%0.00%0.00%0.00%-15.91%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
-11.88%-11.88%-19.43%-17.54%-84.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Precipio, Inc. stock logo
PRPO
Precipio
1.1174 of 5 stars
0.03.00.00.02.72.50.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.0802 of 5 stars
0.05.00.00.04.40.00.0
SeqLL Inc. stock logo
SQL
SeqLL
N/AN/AN/AN/AN/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Precipio, Inc. stock logo
PRPO
Precipio
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
SeqLL Inc. stock logo
SQL
SeqLL
0.00
N/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Precipio, Inc. stock logo
PRPO
Precipio
$18.53M0.54N/AN/A$10.16 per share0.65
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.97M0.37N/AN/A$3.01 per share1.05
SeqLL Inc. stock logo
SQL
SeqLL
$80K0.00N/AN/A$14.70 per share0.00
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$300K8.57N/AN/A$37.95 per share0.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Precipio, Inc. stock logo
PRPO
Precipio
-$5.85M-$2.94N/AN/A-17.23%-34.01%-25.27%5/13/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$4.84M-$4.02N/AN/AN/A-26.82%-68.98%-26.39%6/16/2025 (Estimated)
SeqLL Inc. stock logo
SQL
SeqLL
-$4.09M-$16.40N/AN/AN/AN/A-124.09%-64.18%N/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
-$62.01M-$28.02N/AN/AN/A-79.74%-57.16%N/A

Latest SQL, PRPO, TLIS, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2025Q4 2024
Precipio, Inc. stock logo
PRPO
Precipio
$0.74-$0.23-$0.97-$0.23$8.01 million$5.45 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
SeqLL Inc. stock logo
SQL
SeqLL
N/AN/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Precipio, Inc. stock logo
PRPO
Precipio
0.02
0.73
0.60
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.34
2.49
SeqLL Inc. stock logo
SQL
SeqLL
0.50
5.04
5.04
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/A
7.76
7.76

Institutional Ownership

CompanyInstitutional Ownership
Precipio, Inc. stock logo
PRPO
Precipio
10.45%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
SeqLL Inc. stock logo
SQL
SeqLL
1.82%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
43.77%

Insider Ownership

CompanyInsider Ownership
Precipio, Inc. stock logo
PRPO
Precipio
13.30%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
SeqLL Inc. stock logo
SQL
SeqLL
22.30%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
46.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Precipio, Inc. stock logo
PRPO
Precipio
601.52 million1.29 millionNo Data
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.62 million1.55 millionNot Optionable
SeqLL Inc. stock logo
SQL
SeqLL
7381,000296,000Not Optionable
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
2601.82 million984,000No Data

Recent News About These Companies

Talis Biomedical (NASDAQ:TLIS) Trading Down 11.9% - Time to Sell?
Talis Biomedical Corp Ordinary Shares
Why Is Talis Biomedical (TLIS) Stock Down 52% Today?
(TLIS) Trading Report
Talis Biomedical Corp (TLIS)
Talis Biomedical Corporation (TLIS)
TLIS Feb 2024 2.500 put
LICY, BTAI and HROW among mid-day movers

New MarketBeat Followers Over Time

Media Sentiment Over Time

Precipio stock logo

Precipio NASDAQ:PRPO

$6.65 +0.02 (+0.24%)
Closing price 05/12/2025 03:58 PM Eastern
Extended Trading
$6.37 -0.28 (-4.15%)
As of 05/12/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.17 +0.02 (+0.63%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$3.09 -0.08 (-2.49%)
As of 04:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

SeqLL stock logo

SeqLL NASDAQ:SQL

SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.

Talis Biomedical stock logo

Talis Biomedical NASDAQ:TLIS

$1.41 -0.19 (-11.88%)
As of 05/12/2025 11:23 AM Eastern

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.